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Catatonia is a severe motor syndrome with an estimated prevalence among psychiatric
inpatients of about 10%. At times, it is life-threatening especially in its malignant form
when complicated by fever and autonomic disturbances. Catatonia can accompany many
different psychiatric illnesses and somatic diseases. In order to recognize the catatonic syn-
drome, apart from thorough and repeated observation, a clinical examination is needed.
A screening instrument, such as the Bush-Francis Catatonia Rating Scale, can guide the
clinician through the neuropsychiatric examination. Although severe and life-threatening,
catatonia has a good prognosis. Research on the treatment of catatonia is scarce, but there
is overwhelming clinical evidence of the efficacy of benzodiazepines, such as lorazepam,
and electroconvulsive therapy.
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INTRODUCTION
Catatonia is a severe motor syndrome with an estimated preva-
lence among psychiatric inpatients of about 10% (1, 2). Catatonia
can accompany many different psychiatric illnesses and somatic
diseases. A minority of catatonic patients suffers from schizo-
phrenia (30%), while a majority has a bipolar disorder (43%)
(1, 3, 4). Catatonia has also been linked to other psychiatric dis-
orders, such as obsessive-compulsive disorder (5), post-traumatic
stress disorder (6, 7), or withdrawal from alcohol (8) or benzo-
diazepines (9, 10). In up to 25% of cases, catatonia is related
with general medical or neurologic conditions (1, 11). Recently,
it was shown repeatedly that catatonic symptoms are observable
in most patients diagnosed with anti-N -methyl-d-aspartate recep-
tor (anti-NMDAR) encephalitis (12, 13). In adolescents and young
adults with autism, catatonia is found in 12–17% (14). Pediatric
catatonia also emerges in patients with tic disorders, and a variety
of other (developmental) disorders (15). The same principles of
evaluation and treatment seem to apply to pediatric patients as in
adult patients (15, 16).
A life-threatening situation occurs when catatonia is accompa-
nied by fever and autonomic abnormalities. Malignant catatonia,
coined as “lethal catatonia” by Stauder in 1934 (17), presents as
a constellation of catatonia, stuporous exhaustion, autonomic
instability, respiratory failure, collapse, coma, and often death
if left untreated. This clinical picture is very close to what is
observed in neuroleptic malignant syndrome (NMS), which is
considered by several experts to be a drug-induced form of
catatonia (18).
EVALUATION, DIFFERENTIAL DIAGNOSIS, AND TREATMENT
An effective treatment starts with a swift and correct diagnosis. In
any patient exhibiting marked deterioration in psychomotor func-
tion and overall responsiveness, catatonia should be considered.
Moreover, any patient that is admitted to a psychiatric ward with a
severe psychiatric disorder, such as depression, bipolar disorder, a
psychotic disorder, or autism spectrum disorder, should be exam-
ined routinely (19). Some signs and symptoms are evident upon
observation of the patient during a psychiatric interview. Other
specific symptoms, however, such as automatic obedience, ambi-
tendency, negativism should be elicited during a neuropsychiatric
examination (19, 20). A rating scale can be used as a screening
instrument and aid in the detection and quantification of catato-
nia. A number of rating scales have been found reliable, sensitive
and specific: the Rogers Catatonia Scale, the Bush-Francis Catato-
nia Rating Scale (BFCRS) (and its revised version), the Northoff
Catatonia Rating Scale, and the Braunig Catatonia Rating Scale
(19). Early detection of catatonia is of great importance, since the
presence of catatonic signs possesses significant prognostic and
therapeutic value (19).
Unfortunately, no laboratory test specifically defines catato-
nia. The “diagnostic weight” of several proposed laboratory and
imaging tests is limited (21). Possible laboratory tests, primar-
ily to assess various underlying conditions, include a complete
blood count and metabolic panel, erythrocyte sedimentation
rate, blood urea nitrogen, creatinine, serum iron, and creatinine-
phosphokinase, antinuclear antibodies, and urinalysis, and mag-
netic resonance imaging, electroencephalogram, cerebrospinal
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fluid analysis (4, 11). Given the frequent association with anti-
NMDAR-encephalitis, detection of IgG antibodies to NMDAR in
cerebrospinal fluid or serum is advisable (22). Since serum iron
was found to be reduced in NMS compared to catatonia (23), some
authors see low serum iron as a risk factor for developing NMS
after using antipsychotics in a catatonic patient (24). A drug screen
to detect common illicit and prescribed substances is necessary.
PROGNOSIS
Prognosis of catatonia is good, especially with early and aggressive
treatment. In mood disorders, prognosis is probably better than in
psychotic disorders. Kraepelin, who classified catatonia as a type
of dementia praecox, wrote, in the 9th edition of his textbook,
that almost half of catatonic attacks begin with a depressive phase
and that these patients had a better prognosis. Hoch, in a mono-
graph on benign stupors, reports good outcomes (‘remission and
return to the community ’) in 13 patients with manic-depressive
illness, and a poor outcome in 12 schizophrenics (25). In more
recent studies, results are conflicting. Most of the available data
confirm a worse prognosis in the context of schizophrenia. In a
randomized double-blind, placebo-controlled trial in 18 patients
with chronic schizophrenia, who also displayed enduring catatonic
features, 6 mg lorazepam per day for 12 weeks did not have any
effect on catatonic symptoms (26). In another recent study, 73% of
24 patients with catatonia remitted within 6 days after starting ben-
zodiazepines: partial responders (6/24) all had schizophrenia (27).
In a retrospective study ECT was only partially efficacious in 2 of 4
patients with schizophrenic catatonia, whereas 5 out of 5 patients
with mood disorder fully recovered (28). In a small open study,
however, lorazepam (4–12.5 mg/day) was reported ineffective in 5
of 20 patients; all 5 with mood disorders (29). In a recent retro-
spective chart study on the effects of lorazepam in 107 inpatients
with a primary diagnosis of catatonia, there was no significant
difference between patients with mood disorder and those with
a non-affective psychotic disorder (30, 31). Similarly, in an ECT-
study in 22 patients, 13 (59%) of which had a mood disorder, no
statistically significant difference was found in the effectiveness of
the resolution of catatonic symptoms in persons with mood dis-
order versus schizophrenia (32), although the authors stress that
in the patients with mood disorders more catatonic symptoms
resolved with ECT than in the other group.
A factor that might complicate the difference in reported
response rates of affective versus schizophrenic catatonia is
chronicity. At least part of the studies showing a worse response in
the context of schizophrenia have included patients with chronic
catatonia (4, 26, 33). Some authors have suggested that “chronic
catatonia” in the context of schizophrenia is phenomenologically
different and less responsive to either benzodiazepines or ECT
(34), and thus carries a less favorable prognosis then the acute
forms of catatonia. The fact that a longer duration of the episode
has been reported to predict a worse response should not be seen
as a reason to withhold adequate treatment in patients presenting
with longstanding or resistant catatonic symptoms. Catatonia that
is not effectively treated may persist for years, but should never-
theless be promptly treated upon detection. A number of cases
are illustrative of the overall good prognosis, even in chronic and
longstanding catatonic symptoms. A man with a 17-year history
of catatonia responded swiftly to the administration of lorazepam
(35); a 15-year-old girl with catatonic lupus, resistant to several
treatments was successfully treated with ECT after 3 months (36).
A man developing catatonia after myocardial infarction remained
catatonic for 1.5 years until he was treated with ECT (37). A men-
tally retarded boy with catatonia of 5 year’s duration improved
with lorazepam (38). Both Ripley and Millson (39) and Salam
et al. (40) reported positive response to lorazepam in two patients
with psychogenic catatonia that lasted 2 1/2 years and 3 months,
respectively. A long treatment delay should, however, be avoided
since it can lead to a variety of serious medical complications,
some of which may be lethal (41).
In the above mentioned retrospective lorazepam-study in 107
inpatients (30), predictors of response to lorazepam were exam-
ined. A longer illness duration, the presence of mutism, third-
person auditory hallucinations and ‘made phenomena’ (in which
the individual feels he is being made to do something) predicted a
poor response, whereas the presence of waxy flexibility predicted
a good response (30). It should be noted that low lorazepam doses
(3–6 mg/day) were used. A longer illness duration also seemed to
predict a worse outcome in the first 11 patients treated by László
Meduna, who invented convulsive therapy in 1934 (42, 43). In a
1912 monograph, Urstein reports on 30 patients with catatonia,
with various underlying conditions and a variable prognosis, being
worse in patients with a higher number of episodes (44). Fink states
that prognosis is especially favorable when the syndrome is dom-
inated by stupor, hyperactivity, rapid, and pressured speech, and
lability of mood, or if there is a previous episode with recovery, a
rapid onset of the episode, and good social functioning prior to
the episode (45, 46). Van Waarde and co-workers have examined
predictors of response to ECT in 27 catatonic patients and found
improvement to be significantly associated with younger age, and
the presence of autonomic dysregulation, especially higher body
temperature (47). There is anecdotal evidence that organic catato-
nia is less responsive, or does not respond at all, to ECT. Swartz and
colleagues described four patients with a variety of neurological
impairment (Alzheimer’s disease, post-encephalitic mental retar-
dation, cerebellar atrophy, epilepsy, and spinal injury). Patients
showed only transient and partial improvement to ECT. The
authors suggest that advanced pathological changes of the CNS
might explain a diminished response and that these states require
a particularly intensive treatment (48).
Raffin and coworkers (16) recently reported treatments used
in 66 consecutively hospitalized children and adolescents between
the ages 9–19 with catatonia. The most frequent comorbid condi-
tions were schizophrenia (N = 38, 58%), pervasive developmental
disorder (N = 17, 26%), medical conditions (N = 16, 24%), bipo-
lar disorder (N = 11, 17%), and intellectual disability (N = 8,
12%). The naturalistic design of the study lists a wide range
of treatments in various combinations. Average catatonia scores
decreased and level of function increased during the admission.
Fifty-one (77%) patients received benzodiazepines, in doses up to
15 mg of lorazepam per day, which were effective in 65% of cases.
Twelve (18%) received ECT, in three cases as first-line treatment
(of which two cases had malignant catatonia). One patient with
schizophrenia received maintenance ECT. There was no associa-
tion between sociodemographic variables, except gender (males
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improved less than females) or co-morbid (medical or psychi-
atric) condition, and treatment response. Lower catatonia scores
on admission and acute onset were associated with better clinical
response. Cases with posturing and mannerisms were found to
have less improvement than other cases.
TREATMENT OF CATATONIA
SUPPORTIVE MEASURES
A broad range of complications of catatonia can occur, such as
aspiration pneumonia, dehydration, muscle contractures, pres-
sure ulcers, nutritional deficiencies, severe weight loss, thiamine
deficiency, electrolyte disturbances, urinary tract infections, and
venous thromboembolism (11, 49, 50), some of which can lead
to life-threatening situations. Some patients will require a high
level of nursing care, and IV fluids and/or nasogastric tube feeds,
in order to reduce the risk of morbidity and mortality caused
by immobility, poor nutrition and dehydration (11). Antico-
agulant therapies can be used to prevent deep vein thrombo-
sis/pulmonary embolism in immobile patients (50). Medical com-
plications should be treated lege artis. Given the often dramatic
and prompt improvement of motor immobility after treatment,
the major measure in preventing complications is a prompt diag-
nosis, and a rapid initiation of an adequate treatment of the
catatonic state.
ANTIPSYCHOTICS
All prescribed medications should be evaluated for their poten-
tial to induce catatonic symptoms and discontinued if possible.
There is some ambiguity about the role of antipsychotics but it
is generally encouraged to discontinue antipsychotic treatment
in patients presenting with catatonia (46). In the presence of a
catatonic state, both first and second generation antipsychotics
(SGA) may contribute to maintaining or worsening the cata-
tonic state and increase the risk of developing NMS (51–54).
During a prospective follow-up of 82 patients that had received
antipsychotics at some point when catatonic, NMS developed
in three cases (3.6%) (4), a substantially higher incidence than
the estimated incidence of 0.07–1.8% in all antipsychotics-treated
patients (55). The risk of worsening catatonia appears greater with
neuroleptics and antipsychotics with higher D2-blockade and a
higher potential of causing extrapyramidal side effects (56), but
a worsening of catatonia and precipitation of NMS has also been
reported in association with, e.g., olanzapine (57, 58).
Although it is generally accepted that neuroleptics are inef-
fective in catatonia (59), the role of the SGA in the treatment
of catatonia is more ambiguous, and based on cases mostly with
schizophrenia (21). SGA have weak GABA-agonist activity and
5HT2-antagonism that could stimulate dopamine release in the
prefrontal cortex and thus alleviate catatonic symptoms (11).
Several authors have reported a beneficial effect of SGA, such
as clozapine (60–63), olanzapine (64–66), risperidone (67–70),
and quetiapine (71). In one randomized controlled trial, in 14
stuporous psychotic patients, risperidone (4–6 mg/day) was com-
pared to ECT. ECT-treated patients showed significantly greater
improvement than those receiving risperidone (72).
The use of antipsychotics in the presence of catatonia should be
evaluated in any individual case. We support, however, the general
notion to discontinue neuroleptics because of their inefficacy
and their potential of aggravating the catatonic symptoms. Once
treatment with benzodiazepines or ECT is started and catatonia
improves, there may be a role for SGA to target residual psy-
chotic symptoms such as delusions or hallucinations, especially
in patients with schizophrenia (69), or as a prophylactic treat-
ment in psychotic disorders and mood disorders. SGA with low
D2 blockade (quetiapine, olanzapine) or with D2 partial agonism
(aripiprazole) should be favored in these situations (54).
Patients presenting with both delirium and catatonia warrant
special consideration (73, 74). Catatonia is a frequent feature of
delirious mania, a severe syndrome characterized by the rapid
onset of delirium, mania, and psychosis. Symptoms of catato-
nia and delirium overlap, complicating diagnosis. Moreover, DSM
states that catatonia should not be diagnosed if it occurs during the
course of a delirium. The issue is important because treatments
for catatonia and delirium are different, albeit with overlap. While
delirium is typically treated with (typical or atypical) antipsy-
chotics, the emergence of catatonia may caution against the use
of antipsychotics (75, 76). Moreover, if catatonia is not recognized
in a delirious patient, the withdrawal or withholding of benzo-
diazepines sometimes thought to worsen delirium may induce
catatonia or leave catatonia untreated. Further studies in delirious
patients are needed to aid these treatment dilemmas (77).
DIAGNOSTIC TEST
Benzodiazepines are the mainstay of the treatment of catatonia and
are also helpful as a diagnostic probe. A positive Lorazepam Chal-
lenge Test validates the diagnosis of catatonia. After the patient is
examined for signs of catatonia, 1 or 2 mg of lorazepam is admin-
istered intravenously. After 5 minutes, the patient is re-examined.
If there has been no change, a second dose is given, and the
patient is again reassessed (46, 78). A positive response is a marked
reduction (e.g., at least 50%) of catatonic signs and symptoms, as
measured with a standardized rating scale. Favorable responses
usually occur within 10 min (46). If lorazepam is given intramus-
cularly or per os, the interval for the second dose should be longer:
15′ and 30′, respectively. Many clinicians will share the experi-
ence that a “lorazepam test” not only confirms the diagnosis of
catatonia but that it also makes the underlying psychopathology
apparent “by permitting mute patients to speak” (79). Analogous to
the lorazepam test, a Zolpidem Challenge Test was proposed (80,
81). In this test 10 mg of zolpidem is administered per os and after
30 min the patient is examined. A positive response is a reduc-
tion of at least 50% of the BFCRS-score. After a positive response,
treatment can be initiated.
BENZODIAZEPINES
Benzodiazepines are the first-choice treatment for catatonia,
regardless of the underlying condition. Benzodiazepines are pos-
itive allosteric modulators of GABA-A receptors and will correct
deficient GABA-ergic function in the orbitofrontal cortex (11).
Following a positive Lorazepam Challenge Test, repeated doses of
benzodiazepines can be used as a treatment. Their use is safe,
easy and effective, with remission rates reported to be as high
as 70–80% (4, 27, 82–87). In a naturalistic study of 66 children
and adolescents with catatonia, it was found that benzodiazepines
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improved catatonia in 65% of cases, that there was no relation
between dose and level of improvement, that the dose was higher
in some cases (up to 15 mg of lorazepam) than the dose recom-
mended in pediatric patients, and that side effects were few (16).
In a recent trial in 107 adult inpatients (49% with a psychotic
disorder; 44% with a mood disorder), lower success rates were
reported: two thirds responded but only one third of patients
remitted (30). The authors argue that the lower remission rate
could be explained by a delay between illness onset and treatment
(30) but the doses used in the trial (3–6 mg per day) were inad-
equately low. As described above, it was shown repeatedly that
chronic catatonia associated with schizophrenia is less respon-
sive to benzodiazepines. Beckmann and colleagues, in a 5-year
follow-up study, found benzodiazepines ineffective in the treat-
ment of chronic catatonic schizophrenia (33). A comparable poor
response (to lorazepam 6 mg per day) was shown in a randomized
double-blind, placebo-controlled trial in 18 patients with chronic
catatonia in schizophrenia (26).
Efficacy of benzodiazepines in catatonia is determined by
dosage (75), and doses from 8 to 24 mg lorazepam per day are com-
mon and are tolerated without ensuing sedation, especially when
instituted using daily incremental dosages (77). Most authors sug-
gest starting at 1–2 mg of lorazepam every 4–12 h, and adjusting
the dose in order to relieve catatonia without sedating the patient
(11). With an adequate dose, response is usually seen within 3–
7 days (75), but is some cases, response can be gradual and slow
(38). If high dosages of lorazepam are used, patients should be
monitored carefully for excessive sedation and respiratory com-
promise (77). The issue of whether some benzodiazepines are
more efficacious in catatonia has not been cleared. Lorazepam is
generally accepted to be a first-choice drug, demonstrating a 79%
remission rate and the highest frequency of use (84). Successful use
of diazepam (86–90), oxazepam (91), or clonazepam (27, 92–95)
has also been reported. There is no consensus on how long benzo-
diazepines are to be continued, and generally they are discontinued
once the underlying illness has remitted. In a number of cases,
however, catatonic symptoms will emerge each time lorazepam is
tapered off, urging the clinician to continue benzodiazepines for
an extended period of time (96, 97).
ZOLPIDEM
Zolpidem, a positive allosteric modulator of GABA-A receptors,
seems to be a safe and effective treatment alternative. To our
knowledge, Mastain and colleagues were the first to report a dra-
matic durable improvement of catatonia, resistant to ECT and
benzodiazepines, with zolpidem in a 56-year-old woman that was
in a catatonic state secondary to a subcortical stroke (98). Two
years later, the same group presented an open study with zolpi-
dem in seven catatonic patients, observing remission of catatonic
symptoms in five of them within 15–30 min after ingestion, last-
ing 2–5 h (99). They observed these therapeutic effects at a plasma
concentration between 80 and 130 ng/L. They also published a
case report about catatonia in a 21-year-old woman, resolving
15 min after administration of zolpidem as the plasma concentra-
tion reached a peak level of 90 ng/mL. Relapse occurred after 4 h
when plasma concentrations fell below 90 ng/mL (80). In a subse-
quent publication of the same French group, the authors confirm
a prompt response (i.e., reduction of at least 50% of symptoms)
in all patients 20 min after the administration of 10 mg zolpidem,
at a plasma level of 80–150 ng/L (29). These favorable results are
replicated in a few case reports (100–102). In some instances, the
beneficial response to zolpidem occurred after treatment with ben-
zodiazepines and/or ECT had failed (98, 101, 102). These data have
led to the proposition of a Zolpidem Challenge Test (see higher),
and have urged some clinicians to continue treatment with zolpi-
dem instead of benzodiazepines, using doses from 7.5 to 40 mg per
day, without noticeable adverse effects. Even though the short-half
life results in a transient effect on symptoms, long-term treatment
with zolpidem has also been described (101, 102).
GLUTAMATE ANTAGONISTS
Because of its N -methyl-d-aspartic acid (NMDA) antagonist
properties, amantadine (100–500 mg three times a day), and its
derivative memantine (5–20 mg/day), have been tried in catato-
nia. Carroll and coworkers identified 25 cases of amantadine and
memantine use in the treatment of catatonia (103). All cases (16/25
were psychotic disorders) were substantially improved, mostly
after 1–7 days. It should be noted, however, that six of these cases
were unpublished, and that seven other were cases experiencing
a “catatonia-parkinsonian syndrome” while under treatment with
the high-potency neuroleptic drugs haloperidol or fluphenazine.
The symptoms diminished when neuroleptics were tapered and
amantadine was added (104, 105). Since then, eleven additional
cases describing the successful use of amantadine or memantine
in catatonia have been published (58, 105–110). In one case, in an
adolescent girl, catatonia that was resistant to ECT improved after
the addition of amantadine (58). Only in a review of Hawkins
and coworkers, a case is reported in which the use of amanta-
dine remained without effect (84). It should be acknowledged,
however, that negative cases are less likely to be published. Never-
theless, given these positive signals in the published literature, and
evidence of its efficacy in treating the negative and cognitive symp-
toms of schizophrenia, amantadine should be further studied as a
possible treatment option for catatonia.
OTHER AGENTS
There is anecdotal evidence from case-reports on the use of various
other pharmacological agents, such as bromocriptine (111) and
biperiden (112). Based on the GABA-hypothesis of catatonia, and
the GABA-related working mechanism of several anti-convulsive
mood stabilizers, these drugs have been proposed as a possible
treatment option for the treatment of catatonia in bipolar patients.
Only a few case-reports have been published. Valproate was used in
several case reports (113–115), and found not only to have prophy-
lactic effects but also“an ameliorating effect on the catatonic symp-
toms”(116). In a single case report, levetiracetam was advocated as
a treatment for catatonia in bipolar disorder (117), given its possi-
ble mood stabilizing efficacy. It is of note, however, that levetirac-
etam has also been described to provoke catatonia (118). The use of
topiramate (119) and carbamazepine (120) has also been reported.
Although lithium has been anecdotally reported to have a bene-
ficial effect on acute catatonic symptoms (121, 122), it is mostly
described to be of use in the prevention of recurrent catatonia
(121, 123–127), albeit with sometimes limited results (123).
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ELECTROCONVULSIVE THERAPY
Electroconvulsive therapy should be started in a patient with cata-
tonia that is not responding to benzodiazepines or when a decisive
and rapid response is required in severe cases with life-threatening
conditions such as malignant catatonia featuring high idiopathic
fevers, tachycardia, severe blood pressure changes. If the under-
lying condition, e.g., psychotic depression, warrants ECT, this
treatment may as well become the treatment of first choice.
The excellent efficacy of ECT in catatonia is generally acknowl-
edged, even in the absence of randomized controlled evidence.
The guidelines for the use of neurostimulation therapies in major
depressive disorder of the Canadian Network for Mood and Anxi-
ety Treatments define catatonia as one of the indications in which
ECT should be considered as a first-line treatment (128).
Response rates in ECT are not systematically studied, but it is
efficacy is described in hundreds of case reports and some small
studies. In a review paper, Hawkins et al. reported an 85% (47/55)
complete response rate (84). To our knowledge, only one ran-
domized controlled ECT trial has been published. In this trial, the
efficacy of ECT (BT, 3/W, N = 8) plus oral placebo was compared
with sham ECT plus risperidone in lorazepam non-responsive
non-affective catatonia. BFCRS scores reduced markedly, but the
reduction was significantly more profound in the ECT group (72).
Suzuki and co-workers studied both short- and long-term efficacy
of ECT in intractable catatonic schizophrenia. In the acute phase,
100% of 11 patients responded to ECT. Relapse occurred in seven
cases, and all occurred within 6 months. The 1-year recurrence
rate was 63.6%, despite continuation pharmacotherapy (129).
Relapsers received a second course of ECT followed by mainte-
nance ECT for 1 year and four remained in remission (130). Those
who relapsed again could be treated successfully with adjusting the
frequency of treatment sessions (131). In another Japanese study,
the efficacy of ECT was shown very clearly (132). Fifty patients
presenting with catatonic symptoms, 23 of whom were diagnosed
with schizophrenia, received either ECT or a benzodiazepine as
first-line treatment. If benzodiazepines were ineffective, the next
step was either ECT or an antipsychotic drug; if the latter failed,
ECT was the last resort. Only 1 of 41 patients responded fully
to benzodiazepines, and 19 responded partially. In contrast, all 17
patients who received ECT achieved remission. Payee and cowork-
ers confirmed these favorable results: 8 of 9 (89%) lorazepam-
non-responders responded to ECT (85). In another small (N= 9)
prospective comparative study Escobar and colleagues (133) noted
that catatonic symptoms remitted faster and to a greater extent in
the depressed patients (4/9) than in those with schizophrenia (5/9).
In seven retrospective chart reviews, with a total of 222 patients,
mostly benzodiazepine-non-responders, high response rates are
confirmed (Table 1). The largest and most informative study
included a chart review of 250 patients with catatonic schizophre-
nia, and was part of the Iowa 500 project (134). Eighty-five (40%)
patients remitted (regardless of treatment used), while 53% of the
75 patients who had received ECT remitted. Another retrospec-
tive chart review was conducted in a university-affiliated inpatient
unit. Seven of 19 patients presenting with catatonia were diagnosed
with schizophrenia and ECT was used in four of them, expe-
riencing partial (N = 3) or considerable (N = 1) improvement.
In contrast, five out of five patients with mood disorder fully
recovered after receiving ECT (28).
Rohland et al. reported ECT to be effective in 93% (26/28) of
patients with catatonia admitted to an inpatient psychiatric unit
(32). England et al. reported dramatic improvement in 10 of 12
(83%) patients with catatonia after 1–5 ECT sessions (63). In the
largest study to date, 63 patients with catatonia (30% schizophre-
nia; 41% mood disorders) received bilateral ECT, thrice weekly,
either as a first choice (n= 6), or after lorazepam had failed
(n= 57). Fifty-six patients (89%) responded to ECT. Patients
who responded in 4 sessions (31/56; 55%) had a lower duration
of catatonia, a higher BFCRS-score, more often waxy flexibility
and Gegenhalten, the involuntary resistance to passive movement
of the extremities. Echophenomena predicted a slower response
(136). The lowest response rates were reported in a retrospective
study of 27 patients, treated with bitemporal ECT, often daily dur-
ing the first week (47). Response rates were 59%. Probably, the
smaller proportion of patients with a primary mood disorder, a
significant treatment delay (a mean time interval of 2 months)
may have negatively influenced treatment response. Another pos-
sible explanation is the fact that one third of the patients had been
exposed to antipsychotics before ECT, which was reported earlier
to be related to a decreased effectiveness (84).
The successful use of ECT in chronic catatonia has been
described in a few case reports (137–140). Duration of catato-
nia varied from 3 months to 12 years, and in some cases protracted
courses of bitemporal ECT (e.g., 17–68 treatments (138, 140) were
needed to achieve a response. In several of these chronic cases, the
catatonic symptoms reappeared when ECT was stopped. Some
patients with chronic catatonia in schizophrenia will respond to a
Table 1 | ECT in catatonia: retrospective chart reviews.
Author(s), year ECT EP/Schedule Mood (%)/psychotic disorder (%) N responders/N total Responders (%)
Morrison (134) NA/NA 0/100 40/75 53
Pataki (28) BT/NA 56/44 6/9 67
McCall (135) BT/NA 75/12 7/8 88
Rohland (33) BT/3*W 59/23 26/28 93
van Waarde (47) BT (93%)/daily [first week (56%)] 48/44 16/27 59
England (63) BT/NA NA 10/12 83
Raveendranathan (136) BT/3*W 41/30 56/63 89
EP, electrode position; BT, bitemporal; N, number; NA, not available.
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combination of ECT and clozapine. In a retrospective study, this
combination resulted in sound clinical improvement as measured
with the clinical global impression (CGI) in 22 patients (141).
A recent systematic review of treatment of (severe) autistic cata-
tonia identified 12 cases with autism and catatonic symptoms of a
few months to around 6 years’ duration, treated with ECT-courses
that ranged from 7 to 29 sessions. Almost all cases reported a dra-
matic improvement with ECT, usually after relatively few sessions.
A few papers report a more mixed response to ECT. Several cases
reported rapid recurrence of symptoms when ECT was discontin-
ued or suspended (142). Consoli et al collected 59 cases of children
and adolescents with catatonia treated with ECT. Response to ECT
was favorable for 45 patients (76%), with partial improvement
noted in 3 (5%) and a lack of response in only one (143).
Recently, several authors report on the successful use of uni-
lateral ECT in a total number of 21 cases (36, 144), 15 of
which were treated with an ultra-brief pulse (UB) width (139,
145, 146). In a case-series of 5 patients with catatonia, resistant
to benzodiazepines, 4 patients experienced a full response with
unilateral ECT; one patient achieved only partial response, and
was switched to bitemporal without experiencing any additional
benefit (144). In the largest case-series to date, of 13 catatonic
patients treated, 11 had rapid symptom resolution with UB right-
unilateral (RUL) ECT with minimal adverse effects. Two patients
who did not improve with RUL ECT were switched to bilat-
eral ECT, which provided no additional symptom benefit (146).
These favorable results probably reflect the high responsiveness
of catatonia to ECT, whatever technique is used. Most authors,
however, strongly recommend bilateral ECT at substantially supra-
threshold stimulus dosing in severely ill patients, arguing that
there is substantially more evidence, and that transient cognitive
impairment is a secondary consideration in patients with severe
catatonia (41, 147).
It is generally advised to stop psychopharmacological agents
prior to initiation of ECT. When there was a partial response
with benzodiazepine treatment, it might be unwise to abruptly
discontinue this treatment, because of possible interference with
seizure threshold and the risk of aggravating the catatonic state.
Lorazepam and ECT can be given concurrently. If lorazepam inter-
feres with eliciting seizures, flumazenil, a partial benzodiazepine
antagonist, can be given just before the anesthetic (75).
The number of treatments, before substantial and sustained
improvement becomes obvious, cannot be predicted. Often, a
rapid response is seen, after one or a few treatment sessions (63,
136), but sometimes catatonia seems to require more treatments
than is necessary for the relief of major depression (138, 140).
Therefore, ECT treatment must be individually tailored. In severe
or malignant catatonia, daily (“en bloc”) treatments for three to
5 days may be necessary. Maintenance-ECT may be useful for
sustained symptom-remission.
TRANSCRANIAL MAGNETIC STIMULATION
The successful use of rTMS was reported in four cases, after 7–10
high-frequency stimulation sessions of the dorso-lateral prefrontal
cortex (148–151). In one case, a 45-year-old man with schizo-
phrenia, previously recovering from catatonia with ECT failed to
improve with rTMS (152).
CONCLUSION
Catatonia is a severe psychomotor syndrome with an excellent
prognosis if recognized and treated appropriately. The treatment
of catatonia in children and adolescents should follow the same
principles as in adults. Great care should be taken to avoid (med-
ical) complications. Although a number of pharmacological agents
have been tried successfully in catatonia, rarely, if ever, the effect
is as immediate and dramatic as seen with benzodiazepines. If
lorazepam is not available, zolpidem can be used as a diagnostic
probe, and probably as a treatment alternative. If benzodiazepines
fail (inadequate or transient response, excessive sedation), ECT
should be started without delay. If the underlying condition war-
rants ECT-treatment, or in life-threatening situations like malig-
nant catatonia or NMS, ECT is the treatment of first choice. It
is advised to choose the most efficacious technique, i.e., bilat-
eral standard-pulse ECT with a stimulus dose that is substantially
above the seizure threshold.
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